DOCSLIB.ORG

2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Copenhagen University Research Information System 2015 ACVIM Small Animal Consensus Statement on seizure management in dogs Podell, M.; Volk, H. A.; Berendt, Mette; Löscher, W.; Muñana, K.; Patterson, E. E.; Platt, S. R. Published in: Journal of Veterinary Internal Medicine DOI: 10.1111/jvim.13841 Publication date: 2016 Document version Publisher's PDF, also known as Version of record Document license: CC BY-NC Citation for published version (APA): Podell, M., Volk, H. A., Berendt, M., Löscher, W., Muñana, K., Patterson, E. E., & Platt, S. R. (2016). 2015 ACVIM Small Animal Consensus Statement on seizure management in dogs. Journal of Veterinary Internal Medicine, 30(2), 477-490. https://doi.org/10.1111/jvim.13841 Download date: 08. Apr. 2020 ACVIM Consensus Statement J Vet Intern Med 2016;30:477–490 Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incor- porated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements. 2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs M. Podell, H.A. Volk, M. Berendt, W. Loscher,€ K. Munana,~ E.E. Patterson, and S.R. Platt This report represents a scientific and working clinical consensus statement on seizure management in dogs based on cur- rent literature and clinical expertise. The goal was to establish guidelines for a predetermined, concise, and logical sequential approach to chronic seizure management starting with seizure identification and diagnosis (not included in this report), reviewing decision-making, treatment strategies, focusing on issues related to chronic antiepileptic drug treatment response and monitoring, and guidelines to enhance patient response and quality of life. Ultimately, we hope to provide a foundation for ongoing and future clinical epilepsy research in veterinary medicine. Key words: Cerebrospinal fluid; Dogs; Epilepsy; Magnetic resonance imaging; Neurologic disorder. pileptic seizures are a common neurologic disorder Ein dogs characterized by a wide spectrum of clinical Abbreviations: signs and consequences. Variable short- and long-term AED antiepileptic drugs morbidity effects occur caused both by the disease and ESVN/ECVN European Society and College of Veterinary Neurology its treatment. Survivability often is dependent more on ACVIM American College of Veterinary Internal Medicine quality of life and financial issues than actual disease MRI magnetic resonance imaging CT computer tomography CSF cerebrospinal fluid CNS central nervous system From the Medvet Chicago, Medical and Cancer Centers for Pets, ACTH adrenocorticotrophic hormone Chicago, IL (Podell); Department of Neurosurgery, Pritzker School of Medicine, The University of Chicago, Chicago, IL (Podell); t4 thyroxine Department of Clinical Sciences and Services, Small Animal MCT medium chain triglyceride Medicine and Surgery Group, The Royal Veterinary College, QOL quality of life Hatfield, Hertfordshire, UK (Volk); Department of Veterinary and Clinical Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Berendt); manifestations.1,2 As such, the burden is on the clinician Department of Pharmacology, Toxicology and Pharmacy, to balance the variable outcome measures of seizure University of Veterinary Medicine, Hannover, Germany (Lo¨scher); Center for Systems Neuroscience, Hannover, Germany (Lo¨scher); control and owner perception of patient quality of life. Department of Clinical Sciences, College of Veterinary Medicine, Epilepsy is a heterogeneous disease process compli- North Carolina State University, Raleigh, NC (Munana);~ cated by the inability to obtain a definitive diagnosis for Department of Veterinary Clinical Sciences, University of all patients as a consequence of the challenges of limited Minnesota College of Veterinary Medicine, St. Paul, MN diagnostic testing because of financial constraints, unpre- (Patterson); Department of Small Animal Medicine & Surgery, dictability of disease progression, and gaps in scientific College of Veterinary Medicine, University of Georgia, Athens, GA 3–5 (Platt). knowledge of disease pathophysiology. Lack of unifor- Corresponding author: M. Podell, Medvet Chicago, Medical and mity of accepted definitions for seizure type, diagnosis, Cancer Centers for Pets, 3123 N. Clybourn, Chicago, IL 60618; and treatment are being addressed but are complicated e-mail: [email protected]. by wide variations in treatment strategies between pri- Submitted January 4, 2016; Revised January 18, 2016; mary and specialty clinicians alike. Furthermore, a rela- Accepted January 18, 2016. tively small database of strong evidence-based clinical © Copyright 2016 The Authors. Journal of Veterinary Internal studies exists for the ever-changing number of antiepilep- Medicine published by Wiley Periodicals, Inc. on behalf of the Ameri- can College of Veterinary Internal Medicine. tic drugs (AED) designed for human use. As a result, This is an open access article under the terms of the Creative many primary care clinicians are left to treat epilepsy Commons Attribution-NonCommercial License, which permits use, with lack of uniform, scientifically based guidelines. distribution and reproduction in any medium, provided the original The International Veterinary Epilepsy Task Force work is properly cited and is not used for commercial purposes. recently published collaborative consensus statements DOI: 10.1111/jvim.13841 478 Podell et al on epilepsy classification3, diagnostic approaches,6 treat- have been identified in epileptic people, including a ment,7 and therapeutic outcome measures.4 These diagnosis of current or previously defined cerebral papers have created a working foundation for the lesions or trauma, presence of interictal EEG epileptic advancement of veterinary epileptology. discharges (up to 90% recurrence rate) and a history of The purpose of this paper was to build on previous marked postictal adverse effects.13,14 Evidence-based work by providing a scientific and working clinical con- guidelines from several international groups are well sensus statement on seizure management in dogs based established for people based on risk-benefit ratio and on current literature coupled with clinical expertise. The predictability factors of drug effect.15–17 From these goal is to establish guidelines for a predetermined, con- guidelines, several commonalities exist in guiding clini- cise, and logical sequential approach to seizure manage- cal practice including confirmation of an epileptic sei- ment starting with seizure identification and diagnosis zure event and seizure type, obtaining a definitive (not included in this report), reviewing decision-making, diagnosis, knowledge that recurrent seizure activity is treatment strategies, focusing on issues related to correlated with poorer long-term treatment success, chronic AED treatment response and monitoring, and and the influence of treatment on quality-of-life concluding with guidelines to enhance patient response (QOL) factors.18 Thus, the decision to treat is a and quality of life. Ultimately, we hope to provide a reflection of the treatment goals to decrease or elimi- foundation for ongoing and future clinical epilepsy nate epileptic events, decrease seizure severity, avoid research in veterinary medicine. adverse effects, and decrease seizure-related mortality and morbidity.7,19,20 Methodology Although similar information is not as readily avail- able for dogs, extrapolation can provide rational treat- The consensus was reached based on the available ment guidelines. Overwhelming evidence exists in published evidence in the peer-reviewed literature, people that there is no benefit to starting treatment including proceedings of Annual Congresses of the after a single unprovoked event.14 The earlier AED European Society and College of Veterinary Neurology treatment is started; however, the better the potential (ESVN ⁄ ECVN) and the American College of Veteri- outcome may be for seizure control.21–23 Recurrent nary Internal Medicine (ACVIM). Aside from searching epileptic seizures can increase epileptogenesis and drug the standard electronic databases Pub Med (www.ncbi. resistance in a subgroup of patients.24,25 Prolonged nlm.nih.gov/PubMed), CAB Abstracts (www.cabdirect. and acute repetitive seizures can increase patient mor- org), and Web of Science (http://wok.mimas.ac.uk), bidity and require prolonged hospitalization with asso- search strategies included reference lists of published ciated financial burden. Comparable information is not papers and proceedings of the aforementioned relevant available for dogs. scientific conferences. Studies were included following The panel recommendations
Load more

Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • MIRENA Data Sheet Vx3.0, CCDS 25 1
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME MIRENA 52 mg intrauterine contraceptive device (release rate: 20 microgram/24 hours) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION MIRENA is an intrauterine system (IUS) containing 52 mg levonorgestrel. For details of release rates, see Section 5.2. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM MIRENA consists of a white or almost white drug core covered with an opaque membrane, which is mounted on the vertical stem of a T-body. The vertical stem of the levonorgestrel intrauterine system is loaded in the insertion tube at the tip of the inserter. Inserter components are an insertion tube, plunger, flange, body and slider. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. Brown coloured removal threads are attached to the loop. The T-body of MIRENA contains barium sulfate, which makes it visible in X-ray examination. The IUS and inserter are essentially free from visible impurities. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Contraception Treatment of idiopathic menorrhagia provided there is no underlying pathology. Prevention of endometrial hyperplasia during estrogen replacement therapy MIRENA Data Sheet Vx3.0, CCDS 25 1 4.2 Dose and method of administration MIRENA is inserted into the uterine cavity. One administration is effective for five years. The in vivo dissolution rate is approximately 20 microgram/24 hours initially and is reduced to approximately 18 microgram/24 hours after 1 year and to 10 microgram/24 hours after five years. The mean dissolution rate of levonorgestrel is about 15 microgram /24 hours over the time up to five years.
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva
    REVIEW ARTICLE Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva Philip N. Patsalos, FRCPath, PhD*† and Dave J. Berry, FRCPath, PhD† INTRODUCTION Abstract: Blood (serum/plasma) antiepileptic drug (AED) therapeu- Measuring antiepileptic drugs (AEDs) in serum or tic drug monitoring (TDM) has proven to be an invaluable surrogate plasma as an aid to personalizing drug therapy is now a well- marker for individualizing and optimizing the drug management of established practice in the treatment of epilepsy, and guidelines patients with epilepsy. Since 1989, there has been an exponential are published that indicate the particular features of epilepsy and increase in AEDs with 23 currently licensed for clinical use, and the properties of AEDs that make the practice so beneficial.1 recently, there has been renewed and extensive interest in the use of The goal of AED therapeutic drug monitoring (TDM) is to saliva as an alternative matrix for AED TDM. The advantages of saliva ’ fl optimize a patient s clinical outcome by supporting the man- include the fact that for many AEDs it re ects the free (pharmacolog- agement of their medication regimen with the assistance of ically active) concentration in serum; it is readily sampled, can be measured drug concentrations/levels. The reason why TDM sampled repetitively, and sampling is noninvasive; does not require the has emerged as an important adjunct to treatment with the expertise of a phlebotomist; and is preferred by many patients, AEDs arises from the fact that for an individual patient
    [Show full text]
  • Results of a Nationwide Veterans Administration Cooperative Study Comparing the Efficacy and Toxicity of Carbamazepine, Phenobarbital, Phenytoin, and Primidone
    Epilepsin, 28(Suppl. 3):SSO-S58, 1987 Raven Press, Ltd., New York 0 International League Against Epilepsy Results of a Nationwide Veterans Administration Cooperative Study Comparing the Efficacy and Toxicity of Carbamazepine, Phenobarbital, Phenytoin, and Primidone Dennis B. Smith, "Richard H. Mattson, ?Joyce A. Cramer, $Joseph F. Collins, §Robert A. Novelly, [[BruceCraft, and the Weterans Administration Epilepsy Cooperative Study Group Good Samaritan Hospital & Medical Center, Portland Oregon; *Yale University School of Medicine, New Haven, Connecticut; $Veterans Administration Cooperative Studies Program, Perry Point, Maryland; *f§Veterans Administration Hospital, West Haven, Connecticut; and llNeurology Service, Veterans Administration Medical Center, Augusta, Georgia, U.S.A. Summary: In 1985 a 5-year multicenter Veterans Admin- sociated with significantly lower incidences of intolerable istration Cooperative Study was completed that com- side effects than were primidone or phenobarbital. A be- pared the efficacy and toxicity of phenobarbital, car- havioral toxicity battery was performed whenever pos- bamazepine, phenytoin, and primidone in a double-blind sible prior to administration of any antiepileptic drug and prospective study design. A total of 622 patients, either at 1, 3, 6, and 12 months after initiation of monotherapy. previously untreated or undertreated, were entered into Significant differences in performance on all subtests of the study. Strict exclusion criteria limited confounding the battery were found between patients with epilepsy factors such as drug or alcohol abuse. Results showed and a control group matched by age, sex, and education. that each of the four drugs used as monotherapy were When the differential effects of all four drugs on behav- similarly effective in the treatment of generalized tonic- ioral toxicity were compared, few statistically significant clonic seizures, but carbamazepine was significantly differences emerged.
    [Show full text]
  • 2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs
    2015 ACVIM Small Animal Consensus Statement on seizure management in dogs Podell, M.; Volk, H. A.; Berendt, Mette; Löscher, W.; Muñana, K.; Patterson, E. E.; Platt, S. R. Published in: Journal of Veterinary Internal Medicine DOI: 10.1111/jvim.13841 Publication date: 2016 Document version Publisher's PDF, also known as Version of record Document license: CC BY-NC Citation for published version (APA): Podell, M., Volk, H. A., Berendt, M., Löscher, W., Muñana, K., Patterson, E. E., & Platt, S. R. (2016). 2015 ACVIM Small Animal Consensus Statement on seizure management in dogs. Journal of Veterinary Internal Medicine, 30(2), 477-490. https://doi.org/10.1111/jvim.13841 Download date: 28. Sep. 2021 ACVIM Consensus Statement J Vet Intern Med 2016;30:477–490 Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incor- porated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited before publication. The authors are solely responsible for the content of the statements.
    [Show full text]
  • 5 Clinical Pearls for Contraception and Preconception Counseling
    EDITORIAL Women with epilepsy: 5 clinical pearls for contraception and preconception counseling For women with epilepsy, intrauterine devices are the optimal reversible contraceptive, and, preconception, the use of antiepileptic drugs with the lowest teratogenic potential should be considered Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital, Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School, Boston n 2015, 1.2% of the US population bazepine (Aptiom), felbamate (Fel- becoming pregnant while taking the was estimated to have active epi- batol), oxcarbazepine (Trileptal), oral contraceptive.6 Carbamazepine, Ilepsy.1 For neurologists, key goals perampanel (Fycompa), phenobarbi- a strong inducer of hepatic enzymes, in the treatment of epilepsy include: tal, phenytoin (Dilantin), primidone was the most frequently used AED in controlling seizures, minimizing (Mysoline), rufinamide (Banzel), this sample. adverse effects of antiepileptic drugs and topiramate (Topamax) (at dos- Many studies report that carba- (AEDs) and optimizing quality of ages >200 mg daily). According to mazepine accelerates the metabo- life. For obstetrician-gynecologists, Lexicomp, the following AEDs do not lisms of estrogen and progestins and women with epilepsy (WWE) have cause clinically significant changes reduces contraceptive efficacy. For unique contraceptive, preconcep- in hepatic enzymes that metabolize example, in one study 20 healthy tion, and obstetric needs that require steroid hormones: acetazolamide women were administered an ethi- highly specialized approaches to (Diamox), clonazepam (Klonopin), nyl estradiol (20 µg)-levonorgestrel care. Here, I highlight 5 care points ethosuximide (Zarontin), gabapentin (100 µg) contraceptive, and randomly that are important to keep in mind (Neurontin), lacosamide (Vimpat), assigned to either receive carbamaze- when counseling WWE.
    [Show full text]
  • APTIOM (Eslicarbazepine Acetate) Is (S)-10-Acetoxy-10,11-Dihydro-5H­ Dibenz[B,F]Azepine-5-Carboxamide
    HIGHLIGHTS OF PRESCRIBING INFORMATION Monitor and discontinue if another cause cannot be established. (5.2, 5.3, These highlights do not include all the information needed to use 5.4) APTIOM safely and effectively. See full prescribing information for • Hyponatremia: Monitor sodium levels in patients at risk or patients APTIOM. experiencing hyponatremia symptoms. (5.5) • Neurological Adverse Reactions: Monitor for dizziness, disturbance in gait APTIOM® (eslicarbazepine acetate) tablets, for oral use and coordination, somnolence, fatigue, cognitive dysfunction, and visual Initial U.S. Approval: 2013 changes. Use caution when driving or operating machinery. (5.6) • Withdrawal of APTIOM: Withdraw APTIOM gradually to minimize the ---------------------------RECENT MAJOR CHANGES-------------------------­ risk of increased seizure frequency and status epilepticus. (2.6, 5.7, 8.1) Indications and Usage (1) 9/2017 • Dosage and Administration (2) 9/2017 Drug Induced Liver Injury: Discontinue APTIOM in patients with jaundice Warnings and Precautions (5) 9/2017 or evidence of significant liver injury. (5.8) • Hematologic Adverse Reactions: Consider discontinuing. (5.10) ----------------------------INDICATIONS AND USAGE--------------------------­ APTIOM is indicated for the treatment of partial-onset seizures in patients 4 ------------------------------ADVERSE REACTIONS------------------------------­ years of age and older. (1) • Most common adverse reactions in adult patients receiving APTIOM (≥4% and ≥2% greater than placebo): dizziness, somnolence, nausea, headache, ----------------------DOSAGE AND ADMINISTRATION----------------------­ diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor. (6.1) • Adult Patients: The recommended initial dosage of APTIOM is 400 mg • Adverse reactions in pediatric patients are similar to those seen in adult once daily. For some patients, treatment may be initiated at 800 mg once patients. daily if the need for seizure reduction outweighs an increased risk of adverse reactions.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Therapeutic Drug Monitoring of Antiepileptic Drugs in Serum: a Fully Automated Approach
    PO-CON1775E Therapeutic drug monitoring of Antiepileptic drugs in serum: a fully automated approach ASMS 2017 TP450 Davide Vecchietti1, Claudio Ghilardi1, Katharina Kern2, Stephane Moreau3, Isabel Cabruja1 1 Shimadzu Italia, Milano, Italy, 2 RECIPE Chemicals + Instruments GmbH, Munich, Germany, 3 Shimadzu Europe GmbH, Duisburg, Germany Therapeutic drug monitoring of Antiepileptic drugs in serum: a fully automated approach Introduction Epilepsy is a chronic neurological disorder which is N-Desmethylmethsuximide NDMS, Oxcarbazepine, characterized by recurrent epileptic seizures whose Phenylethylmalonamide PEMA, Perampanel, Phenobarbital, frequency and rhythm are mostly not predictable. For the Phenytoin, Pregabaline, Primidone, Retigabine, Runamide, pharmacological therapy of epilepsy a variety of Stiripentol, Sulthiame, Tiagabine, Topiramate, Valproic antiepileptic drugs (AEDs) are available today, most of acid, Zonisamide) in serum samples by LC-MS/MS analysis. them exhibit a pronounced intra and inter individual Usually LC-MS/MS analysis of serum samples require variability in pharmacokinetics. For that reason the manual preparation steps for extraction and protein therapeutic drug monitoring of these molecules needs to precipitation before the injection. With the aim to reduce be accomplished by extremely accurate techniques (e.g: the operator involvement and to increase the throughput LC–MS/MS). LC-MS/MS currently lacks in standardization and data quality, we completely eliminated the and throughput for routine analysis. We report
    [Show full text]
  • The Evidence Behind the Treatment of Canine Idiopathic Epilepsy
    The Evidence Behind the Treatment of Canine Idiopathic Epilepsy A Knowledge Summary by Marios Charalambous DVM GPCert(Neuro) RSciMRSB MRCVS1* David Brodbelt MA VetMB PhD DVA DipECVAA MRCVS2 2 Holger Volk DVM PhD DipECVN FHEA MRCVS 1 University College London 2 Royal Veterinary College * Corresponding Author ([email protected]) ISSN: 2396-9776 Published: 11 Feb 2016 in: Vol1, Issue 1 DOI: http://dx.doi.org/10.18849/ve.v1i1.9 Next Review Date: 23 Nov 2017 KNOWLEDGE SUMMARY Clinical bottom line Oral phenobarbital and imepitoin in particular, followed by potassium bromide and levetiracetam are likely to be effective for the treatment of canine idiopathic epilepsy. There is strong evidence supporting the use of oral phenobarbital and imepitoin as ‘first line’ medications. However, there remains a lack of evidence for targeted treatment for the various individual epileptic phenotypes and quite limited evidence on direct comparisons of the efficacy between various anti-epileptic drugs. Question In dogs with epilepsy, what is the best treatment to reduce seizures. Clinical scenario A 5 years old 17 kg German Shepherd intact male dog manifested generalized tonic-clonic seizures one year ago. In the last two months the dog manifested five episodes. The dog is normal between the episodes; idiopathic epilepsy is suspected. You wonder what the best treatment in a dog with presumed idiopathic epilepsy would be. Summary of the evidence Law (2015) Population: Dogs with idiopathic epilepsy (Tier II). Sample size: 21 dogs, n=21 Intervention details: Dogs were fed either ketogenic medium-chain TAG diet (MCTD) or placebo diet for 3 months followed by a subsequent respective switch of diet for a further 3 months.
    [Show full text]
  • Topamax® Tablets and Sprinkle Capsules Topiramate New Zealand Data Sheet
    TOPAMAX® TABLETS AND SPRINKLE CAPSULES TOPIRAMATE NEW ZEALAND DATA SHEET 1. PRODUCT NAME TOPAMAX® 25 mg, 50 mg, 100 mg & 200 mg film-coated tablets TOPAMAX® Sprinkle 15 mg, 25 mg & 50 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION TABLETS Each tablet contains 25 mg, 50 mg, 100 mg or 200 mg of topiramate. Excipient(s) with known effect: Lactose monohydrate For a full list of excipients, see section 6.1. SPRINKLE CAPSULES Each capsule contains 15 mg, 25 mg or 50 mg of topiramate. Excipients with known effect: Sugar For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM TABLETS 25 mg: Round, white, film-coated tablets, marked “TOP” on one side and “25” on the other. 50 mg: Round, light-yellow, film-coated tablets, marked “TOP” on one side and “50” on the other 100 mg: Round, yellow, film-coated tablets, marked “TOP” on one side and “100” on the other 200 mg: Round, salmon, film-coated tablets, marked “TOP” on one side and “200” on the other. SPRINKLE CAPSULES Hard capsules enclosing small, white to off-white spheres. Each gelatin capsule consists of a clear (natural) capsule cap and a white capsule body. 15 mg: imprinted with “TOP” on cap and “15 mg” on body 25 mg: imprinted with “TOP” on cap and “25 mg” on body 50mg: imprinted with “TOP” on cap and “50mg” on body (not marketed). CCDS201005v23 1 TOPAMAX(201215)ADS 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS EPILEPSY TOPAMAX is indicated in adults and children, 2 years and over: • as monotherapy in patients with newly diagnosed epilepsy • for conversion to monotherapy in patients with epilepsy • as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.
    [Show full text]